Innovative Bispecific Nanobody Therapy Targeting TGFB1 and VEGF for Cancer Management

VHH-P535 is a novel humanized bispecific nanobody engineered to simultaneously target transforming growth factor beta 1 (TGFB1) and vascular endothelial growth factors (VEGF). Designed for oncological applications, this therapeutic candidate is currently undergoing biological testing and demonstrates strong potential in cancer treatment. By precisely engaging both TGFB1 and VEGF, VHH-P535 aims to address key molecular drivers of tumor progression and angiogenesis, introducing a promising option for future cancer therapeutics.

Licensing Opportunity

VHH-P535 is currently available for out-licensing and collaborative partnerships. We welcome inquiries from industry partners seeking innovative, differentiated assets for cancer therapeutic development.

Development Phase

Modality

VHH-P535 is designed as a bispecific antibody fusion protein in which an antibody-derived binding fragment that selectively targets VEGF is combined with a humanized single-domain nanobody against TGFB1, and further fused to a human IgG1 Fc region. Expressed in human embryonic kidney cells, this unique modality leverages the compact structure and high stability of nanobodies, paired with the effector functions and favorable pharmacokinetics of the Fc domain. The single-domain configuration offers enhanced tissue penetration and robust molecular interaction, potentially improving therapeutic efficacy within the tumor microenvironment in cancer treatment.

Target

TGFB1 and VEGF are central molecular targets closely associated with cancer pathophysiology. TGFB1 is a multifunctional cytokine from the TGF-beta family, widely expressed in tumor stroma, immune cells, and within the tumor microenvironment, involved in immunosuppression and metastasis. VEGF, a pivotal growth factor, is highly secreted by both malignant and stromal cells, driving angiogenesis and supporting tumor growth. Both TGFB1 and VEGF are instrumental in cancer progression; targeting TGFB1 disrupts immune evasion and metastatic signaling, while inhibiting VEGF blocks abnormal vascularization. The combined targeting of TGFB1 and VEGF via VHH-P535 offers a strategic approach to interrupt multiple cancer-promoting pathways, potentially enhancing anti-tumor outcomes and minimizing resistance mechanisms.

Mechanism of Action

VHH-P535 exerts its therapeutic effects in cancer by concurrently binding and inhibiting TGFB1 and VEGF. Through antagonizing TGFB1, it attenuates immunosuppressive signaling and the pro-metastatic remodeling of the tumor microenvironment. Meanwhile, neutralization of VEGF acts as an angiogenesis inhibitor, restricting the formation of aberrant blood vessels required for tumor growth and dissemination. The synergy from dual pathway modulation disrupts critical signal transduction processes sustaining malignancy. The modular structure of the nanobody platform further enables the extension to other bispecific, multispecific, or even ADC formats, supporting broad applicability and development versatility.

Cancer

Cancer remains a leading cause of morbidity and mortality worldwide, with millions of new cases diagnosed and substantial disease burden across global populations annually. Current therapies—encompassing surgery, radiotherapy, chemotherapy, immunotherapy, and molecularly targeted approaches—have transformed patient outcomes, yet many cancers remain resistant or relapse following initial responses. Limitations include toxicity, non-specificity, development of drug resistance, and the inability to address the complex, multi-factorial nature of tumorigenesis. There is a persistent need for therapeutics that deliver greater efficacy, selectivity, and prolonged responses with improved safety profiles. VHH-P535, with its dual targeting of TGFB1 and VEGF, is uniquely poised to overcome key hurdles in current oncology treatment, potentially suppressing both angiogenesis and tumor-driven immunosuppression, thereby offering new hope for patients inadequately served by existing options.